Investigation on the pathogenesis of membranous nephropathy using anti-PLA2R antibodies and stable podocyte cell line expressing PLA2R

• Project/Area Number: 17K09715
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Kidney internal medicine
• Research Institution: Tokyo Women's Medical University
• Principal Investigator: Katsumata Yasuhiro 東京女子医科大学, 医学部, 講師 (60349719)
• Project Period (FY): 2017-04-01 – 2020-03-31
• Project Status: Completed (Fiscal Year 2019)
• Budget Amount: ¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000); Fiscal Year 2019: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000); Fiscal Year 2018: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000); Fiscal Year 2017: ¥2,990,000 (Direct Cost: ¥2,300,000、Indirect Cost: ¥690,000)
• Keywords: 膜性腎症 / 内科 / 免疫学 / 腎臓学

Outline of Final Research Achievements

This study was aimed to clarify the roles of anti-M-type phospholipase A2 receptor (PLA2R) and anti-PLA2R antibodies in the pathogenesis of idiopathic membranous nephropathy. We successfully developed the human podocyte cell line stably expressing PLA2R. This would have a high impact on the studies of pathogenesis of membranous nephropathy.
We also investigated the clinical usefulness of anti-PLA2R antibodies in patients with membranous nephropathy and compare the three quantification methods. We publish a report on this study.

Academic Significance and Societal Importance of the Research Achievements

本研究課題の主な成果は、PLA2Rの安定形質発現ヒトポドサイト細胞株の作製である。PLA2Rの安定形質発現ヒトポドサイト細胞株については、国内外において従来報告がなく、特発性膜性腎症の病態研究においても高いインパクトがあると考えられる。今後は、このPLA2Rの安定形質発現ヒトポドサイト細胞株を用いて、様々な基礎的研究が行われることが期待される。

Research Products

• [Journal Article] Clinical usefulness of anti-M-type phospholipase-A-receptor antibodies in patients with membranous nephropathy and the comparison of three quantification methods (2020)
  • Author(s): Katsumata Yasuhiro、Okamoto Yuko、Moriyama Takahito、Moriyama Rina、Kawamoto Manabu、Hanaoka Masanori、Uchida Keiko、Nitta Kosaku、Harigai Masayoshi
  • Journal Title: Immunological Medicine Volume: 43 Issue: 1 Pages: 47-56
  • DOI: 10.1080/25785826.2019.1710079
  • Peer Reviewed / Open Access